#BetterMeds4Kids: Accelerating access to better HIV medicines for children

Children are one of the most vulnerable yet neglected population in terms of access to optimal medicines in adapted formulations. Consequently, paediatric therapies often remain limited and sub-optimal. Hear from partners of the Global Accelerator for Paediatric Formulations (GAP-f) WHO network, of which MPP is a founding member, as they share their experiences in developing and improving access to better HIV medicines for children.